← Back to patent-cliff list
Theophylline (Cyrano Therapeutics)
Tier C — Watch / tradeTheophylline (Cyrano Therapeutics)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adenosine receptor, Phosphoric diester hydrolases
Indications (approved)：嗅觉障碍
Regional status
US
Phase II
2023-01-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Theophylline (Cyrano Therapeutics)?
Approved indications include: 嗅觉障碍.
When does the Theophylline (Cyrano Therapeutics) patent expire?
No public expiry year is available for Theophylline (Cyrano Therapeutics) yet; this page updates once verified.
How do I get a quote for Theophylline (Cyrano Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03